Sequentially, profit declined 28.27% from INR 26.42 Cr
Operating revenue grew 23.38% to INR 165.92 Cr during the quarter under review from INR 134.47 Cr in Q3 FY24
Total expenses grew 20.52% to INR 141.85 Cr during the quarter under review from INR 117.69 Cr in Q3 FY24
PharmEasy-owned diagnostics platform Thyrocare’s consolidated net profit zoomed 28.56% to INR 18.95 Cr in the third quarter of the financial year 2024-25 (FY25) from INR 14.74 Cr in the year-ago quarter.
Sequentially, profit declined 28.27% from INR 26.42 Cr.
Operating revenue grew 23.38% to INR 165.92 Cr during the quarter under review from INR 134.47 Cr in Q3 FY24. On a quarter-on-quarter basis, it narrowed 6.45% from INR 177.36 Cr.
Revenue from diagnostic testing services and imaging services rose 24.04% and 13.23% YoY to INR 151.87 Cr and INR 13.43 Cr, respectively.
Total expenses grew 20.52% to INR 141.85 Cr during the quarter under review from INR 117.69 Cr in Q3 FY24. Sequentially, expenses were almost flat.
(The story will be updated soon.)
Comments are closed.